Development and clinical trial of a novel DNA vaccine as immunotherapy during canine Leishmaniasis
| Autor: | Laura Manna, Italia Della Peruta, Angelo Elio Gravino, Elisabetta Coradduzza, Nicoletta Gammarano, Carla Cacciotto, Bernardo Chessa, Alberto Alberti, Marco Pittau, Carlo Maria Del Pizzo, Ilaria Michela Piras, Valentina Ciprì |
|---|---|
| Přispěvatelé: | Manna L., Piras I.M., Cipri V., Alberti A., Peruta I.D., Del Pizzo C.M., Gammarano N., Coradduzza E., Cacciotto C., Pittau M., Gravino A.E., Chessa B., Manna, Laura, P. i. r. a. s., . I. M, Ciprì, V, Alberti, A, Della Peruta, I, Del P. i. z. z. o., . C. M, Gammarano, N, Coradduzza, E, Cacciotto, C, Pittau, M, Gravino, ANGELO ELIO, Chessa, B. |
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
DNA vaccine
medicine.medical_treatment Immunology DNA vaccination Virology Drug Discovery Canine leishmaniasis medicine Dog Immunology and Allergy Leishmania infantum Cytokine biology business.industry Immunotherapy medicine.disease biology.organism_classification Leishmania Clinical trial Real-time polymerase chain reaction Visceral leishmaniasis business VET/05 Malattie infettive degli animali domestici Real-time PCR |
| Popis: | Background: Visceral Leishmaniasis (VL) is a zoonotic disease caused by Leishmaniainfantum in the Mediterranean area. Dogs are the main reservoir of Leishmaniainf antum parasites. Disease management represents a serious problem, since anti-Leishmania drugs have limited efficacy in both symptomatic and asymptomatic dogs, which are infective to phlebotomine vectors. In many tropical and sub-tropical countries the development of a safe and easily-available vaccine has high priority. DNA vaccines represent one of the most recent innovations in the field of immunization. Findings: This study aimed to evaluate the effect of a DNA vaccine based on two Leishmania antigens (Cpb1, PO) in leishmaniotic dogs. Twelve leishmaniotic dogs from a Leishmaniasis-endemic area (Naples, Italy) received three consecutive injections of DNA vaccine at 15-days intervals. Another group of five leishmaniotic dogs received the same amount of pVAX-1 without the coding sequences of Leishmania antigens. Leishmania DNA load, INFγ, IL-4 mRNA expression levels and clinical parameters were tested before and after the therapy, every 3 months for a period of 12 months. Analysis of the data in the vaccinated dogs showed: i) a decrease Leishmania DNA load in lymph node samples, ii) an increase of INFγ and IL-4 mRNA expression levels in PBMC samples. All vaccinated dogs also showed an improvement in the clinical symptoms. Conclusion: Our results show that the vaccine developed in this study may represent a useful tool in the treatment of leishmaniotic dogs. However, since the duration of positive effects is limited in time, further trials are needed to evaluate the effectiveness of immunotherapy alone or in association with conventional therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|